Berlin, Germany, November 06, 2018 / B3C newswire / — ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins announced today that it has completed a cell line development project for one of Zymeworks Inc.’s bispecific antibody program which exceeded expectations. ProBioGen achieved the desired titers in classical fed-batch processes employing its industry-leading CHO.RiGHT® expression & manufacturing platform and its proprietary commercially available chemically defined medium platform. Further, ProBioGen’s proprietary GlymaxX® ADCC enhancement technology was applied.

The project met the primary goals for the bispecific antibody cell line, which were achieving high titers and bispecific purity and maintaining stability during scale-up. Zymeworks is continuing further process development and large-scale production.

Dr. Wieland Wolf, ProBioGen’s Chief Executive Officer, said, “We are very pleased to work with Zymeworks and their industry leading bispecific antibody technology. This project gave us the chance to fully exploit our skills, showcase the experience of our team and the quality of our CHO.RiGHT® expression & manufacturing platform, which we continuously improve and also to apply the unique GlymaxX® technology.”